Since January 3 of this year, Staterra Biopharma (STAB) has been falling steadily from $2.38. There was no single session that could show any recovery. Yesterday the stock closed at $0.9658 on 373k volume leaving no possibility to rise again. Nevertheless, in premarket today it is growing by 19% at the time of writing.
Maybe direct offering of $2 million worth of common shares and warrants. Each share has a price of $1 and the warrants have the same price as well. Hopefully, STAB is rising because of this fixed $1 price tag that was set by the management. It is feared that the stock will continue the downfall unless some success in the research and development happens.